Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients | MicrobiomeTrials← Back to trialsNCT03471117
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
TERMINATEDPHASE4INTERVENTIONAL
Trial Details
Start: 2018-04-01Est. Completion: 2020-01-14
Enrollment target: 5 participants Locations- University of Texas at Arlington, Arlington, Texas, United States
- UT Southwestern, Dallas, Texas, United States
Other microbiome trials you might be interested in
End-Stage Renal DiseaseHemodialysis Complication
This randomized, assessor-blinded controlled trial will evaluate the preliminary efficacy and safety of a 12-week superv…
Isfahan, IranEst. completion Oct 2026
End-stage Chronic Kidney Disease Treated With HemodialysisDepressive Disorders
Hemodialysis is an intensive treatment, with a lifestyle dictated by the organization of the dialysis center. This treat…
Annecy, FranceEst. completion Sep 15, 2028
Phase 2
Recruiting
This study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse. People who have taken a…
Huntsville, United StatesEst. completion Aug 20, 2026